
Position Overview
As a key contributor within the Corporate Strategy function, the Director, Competitive Intelligence will independently lead integrated market and competitive intelligence assessments to inform Korsana’s portfolio strategy. This individual will conduct rigorous primary and secondary research, monitor competitive dynamics and market evolution in strategically relevant indications, and “bring the outside in” by translating complex data into clear, actionable recommendations for executive leadership, IR, R&D, and cross-functional program teams. The role requires strategic thinking, scientific fluency, strong technical communication and critical thinking skills, and hands-on experience with early-stage biotech programs in a fast-paced environment.
Responsibilities
Competitive Intelligence:
Portfolio Assessment / Corporate Strategy:
Education & Experience
Skills & Attributes
The anticipated base salary range for this position is $210,000 - $230,000. This role may also be eligible for a target annual bonus and equity-based compensation, as well as participation in the company’s benefit programs. Actual compensation will depend on several factors, which may include, but are not limited to relevant years of experience, educational background, and geography.
Korsana Biosciences is the sixth groundbreaking company launched by Paragon Therapeutics, a premier biotech incubator founded by Fairmount Funds in 2021, known for its expertise in discovering and developing cutting-edge therapeutic assets in-house.
__
Korsana Biosciences is an Equal Opportunity Employer. We are committed to fostering a diverse, inclusive, and equitable workplace where all individuals are valued and respected. Employment decisions are based on qualifications, merit, and business needs, without regard to race, color, religion, gender, sexual orientation, national origin, disability, veteran status, or any other protected status.
About Us
Korsana Biosciences is a private biopharmaceutical company advancing a pipeline of potential best-in-class therapies for neurodegenerative diseases. In partnership with Paragon Therapeutics, we have developed Therapeutic Targeting (THETA™), a novel blood-brain barrier-penetrant shuttle platform designed to enable dramatically higher drug concentration inside the brain and overcome the limitations of earlier shuttle technologies. Our lead program is KRSA-028, an investigational, shuttled antibody targeting amyloid beta designed to be a best-in-class treatment for Alzheimer’s disease. Our mission is to advance precision-engineered therapies, designed to address some of the biggest unmet needs in medicine. For more information, please visit www.korsana.com
G&A
Waltham, MA
Hybrid
Teilen auf: